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Initial clinical results with the LifeSitet Hemodialysis Access tions, among others, result in patient morbidity and mor-
System. tality and add considerably to the cost of managing
Background. The LifeSitet Hemodialysis Access System is chronic renal failure.a subcutaneous valve with an internal pinch clamp that is actu-
The annual cost of maintaining vascular access in theated with a standard 14-gauge dialysis needle, connected to a
United States is approaching $1 billion [1]. However,single lumen cannula placed in the central venous circulation
for hemodialysis (HD). this represents only the tip of the iceberg. Problems that
Methods. The LifeSite System (2 valves) was implanted in derive both directly and indirectly from these complica-
23 patients with immediate dual-needle HD use. The cannulas tions result in a major proportion of the hospitalizationswere placed in either the jugular or the subclavian veins and
required in this frequently hospitalized population ofwere connected to the subcutaneous valves located in the upper
patients [2].chest area.
Results. The mean duration of device survival for the Life- Since its introduction 21 years ago [3], the polytetra-
Site System was 6.8 6 0.97 months. During this period, the fluoroethylene (PTFE) graft has come to represent the
device achieved prescription HD blood flow rates averaging primary means for delivering HD to patients in the384.7 6 78.5 mL/min with a venous pressure of 223.2 6 60.3
United States. Unfortunately, PTFE grafts are particu-mm Hg. After 125 patient months, device removal because of
larly prone to problems, especially venous stenosis andinfection was at a rate of 2.5 per 1000 days, and there were no
devices removed because of poor flow. The average Kt/V for thrombosis. These problems occur at a rate of approxi-
these patients was 1.51. mately 1 to 1.5 times per patient per year [4]. Cumulative
Conclusion. This preliminary clinical study has validated the patency rates for these devices in most centers are onlyapplicability of the LifeSitet Hemodialysis Access System as
55 to 75% at one year and 50 to 60% at two years [4–9].an access for HD. It is easily implanted and easily used, provides
The obvious solution to the problem of vascular accesssafe and effective dialysis, and is well accepted by patients. It
should be especially useful as a bridge device to allow for in the chronic hemodialysis patient population is to in-
maturation of a native fistula and will provide an alternative crease the use of native arteriovenous fistulae. However,
for long-term use in patients in whom a peripheral dialysis for a variety of reasons, universal usage of this meansaccess is not feasible.
for accessing the patient’s circulation is unlikely to be
realized. There is a definite need for an improved im-
plantable dialysis access system. Toward this goal, theAlthough chronic hemodialysis (HD) is a life-saving
Lifesite Dialysis Systemt (Vasca Inc., Tewksbury, MA,maintenance therapy for end-stage renal disease (ESRD)
USA) has been developed.patients, it is totally dependent on the availability of a
functioning vascular access. Unfortunately, this interface
between the patient and the dialysis machine is defective. METHODS
The vascular access is associated with major complica- Description of the LifeSitet System
tions, including infection, occlusion, increase in cardiac
LifeSitet is a subcutaneous access system that providesload, and quality-of-life impairments. These complica-
immediate central venous access for ESRD patients. This
system consists of an access valve and silicone cannula
(Fig. 1), which is typically implanted below the clavicleKey words: end-stage renal disease, chronic hemodialysis, vascular ac-
cess, dialysis machine. and tunneled to the right internal jugular vein. The valve
is designed so that a standard 14-gauge fistula needleReceived for publication February 15, 2000
actuates an internal pinch clamp as the needle entersand in revised form April 19, 2000
Accepted for publication May 30, 2000 and seals (Fig. 2). Upon removal of the needle, the pinch
clamp closes and flow stops. The LifeSite System alsoÓ 2000 by the International Society of Nephrology
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Fig. 1. The LifeSitet valve with cannula attached.
employs two unique techniques for vascular access. The
first is the repeated use of a single cannulation site in
the patient’s skin, which forms a pain-free tissue tract
called a “buttonhole.” The second is a prophylactic infec-
tion-control technique that involves the in vivo disinfec-
tion of the valve pocket and buttonhole tract by irrigation
with an antimicrobial solution.
Valve and cannula
The valve is approximately 2.48 cm in diameter and
0.68 cm in height and is constructed of stainless steel
and titanium alloy. The valve has a dimpled entrance in
the center of the domed top, which facilitates entry of
a standard 14-gauge dialysis needle (Fig. 1). The circular
ring surrounding the dimpled entrance at the top of the
valve serves as a guide to the needle when the device is
being cannulated. The valve’s stem accepts a 12 French
silicone cannula. The bottom plate of the valve has suture
holes to allow for anchoring of the device at the time of
implantation (Fig. 1).
The fact that the mechanical pinch clamp opens and
closes when the dialysis needle is inserted or removed, Fig. 2. (A) Appearance of 14-gauge fistula needle entering valve with
respectively, prevents any leakage of blood when the pinch clamp closed. (B) Appearance as the fistula needle activates the
internal pinch clamp as it enters valve. Upon removal of the needle,dialysis needle is not seated in the valve and allows for
the pinch clamp closes and flow stops.maintaining the heparin lock within the cannula. Thus,
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there is no possibility for fluid flow when the dialysis pockets are created side by side about 2 to 4 cm below
needle is not in place. the clavicle. These pockets are created beneath the sub-
Once the needle is seated in the metal taper seal, it cutaneous tissue so that the fascia of the muscle forms
is turned approximately one-quarter turn to provide a their floor. The cannulas are then tunneled subcutane-
friction fit that keeps the needle securely in place. A ously to the pockets and cut to the proper length to allow
slight twist and pull of the needle frees it to permit easy for their tips to be located within the right atrium with
withdrawal. The channel for blood passage through the the return cannula being approximately 2 cm longer than
device is smooth without constrictions or dead space. the draw cannula. The final length of the cannulas is
There is therefore no opportunity for the creation of dependent on the individual characteristics of the pa-
turbulence in blood flow. The valve was designed without tient’s body habitus and the exact placement of the
a septum in order to avoid the failures associated with valves. By convention, the medial valve and cannula are
repetitive fistula needle punctures. typically used for draw and the lateral for the return.
At the time of use, the LifeSite System is irrigated After each of the cannulas is attached to the appro-
with an antimicrobial solution using a 25-gauge needle. priate valve, the valve is placed into its pocket and an-
This antimicrobial agent is used for localized prophylaxis chored to the muscle fascia of the pocket floor with
of the LifeSite valve pocket and buttonhole tract prior sutures passed through the holes in the base plate. The
to and following each dialysis treatment. The LifeSite incisions are closed. After placement of the devices is
System was designed to utilize an antimicrobial solution complete, the initial cannulation is made utilizing 14-
in order to help reduce the potential for infection. The gauge dialysis fistula needles. They can be used immedi-
25-gauge needle cannot open or damage the internal ately for dialysis.
pinch clamp, ensuring that the antimicrobial solution is
prevented from entering the circulatory system. Use of the LifeSite System for HD
The 12 French, single lumen, silicone cannula is 34.8 Proper technique for site cleansing, pocket steriliza-
centimeters in length and can be cut to the desired length tion, and needle cannulation and removal is very impor-
at the time of implantation. The distal tip is placed in tant in ensuring the occurrence of minimal complications.
the right atrium and has six side holes located radially At the time of dialysis, the skin over each of the valves
around the axis. These side holes allow for an alternative is first cleansed with a 4% chlorhexidine solution. The
flow path in the presence of fibrin sheathing or in case LifeSite valve and pocket as well as the buttonhole tract
the cannula is positioned against the wall of the vein. are then sterilized using 1 to 3 mL of 0.2% sodium oxy-
chlorosene antimicrobial irrigation solution with a 25-Implantation
gauge needle (Fig. 3).Implantation of the LifeSite System is relatively simple
After the valve is irrigated, it is cannulated using aand can be performed in a radiological or surgical suite.
standard 14-gauge dialysis needle (Fig. 4). A buttonholeIt is important that precautions providing maximum bar-
technique is used for this purpose. This involves ac-rier protection be followed at the time of implantation.
cessing the valve through the same skin site and tissueThe design of the LifeSite Hemodialysis Access Sys-
tract each time the device is cannulated.tem requires that two separate valves be implanted for
Once the needle is seated in the metal taper seal, itHD. The device was designed in this manner to permit
is turned approximately one-quarter turn. The frictionthe flexibility of using two separate implantation sites if
fit of the needle within this taper seal keeps the needleneeded and to permit the replacement of only half of
in the valve securely. With the needle in place, 5 mL ofthe assembly if a problem occurs. Separate valve devices
blood are aspirated to remove the heparin lock and anyalso allow the access system to be used for single needle
blood clots from inside the cannula. The valve is thendialysis as well as for peritoneal dialysis.
flushed with saline and connected to the bloodlines forImplantation of the LifeSite System consists of two
the dialysis session.stages: the subcutaneous implantation of the two valves
At the end of the dialysis session, the LifeSite valvesand the insertion of the two silicone cannulas. The time
are flushed with 10 mL of saline to remove any bloodrequired for implantation is in the range of 1 to 1.5 hours.
that is remaining within the system. A heparin lock isLocal anesthesia and conscious sedation are used for
instilled into each of the cannulas. The needles are thenpatient comfort.
removed with a twist-and-pull motion. After the dialysisThe cannulas are inserted into a central vein, typically
needle has been removed, the valve is again irrigatedthe right internal jugular, although other approaches are
with 1 to 3 mL of 0.2% sodium oxychlorosene solutionavailable (left internal jugular, bilateral approach, exter-
using a 25-gauge needle. The cannulation site is thennal jugular, or subclavian). The cannulas are inserted
scrubbed with 4% chlorhexidine solution, and a nonoc-using the Seldinger technique for central vein cannula-
tion and catheter insertion. Then two subcutaneous valve clusive gauze dressing is applied.
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Fig. 3. Appearance of 25-gauge needle entering valve without dis-
Fig. 4. Fistula needles in place ready for dialysis.turbing the pinch clamp.
dialysis and the absence of an adequately functioning
In vitro studies vascular access, whether a catheter or a peripheral access.
The LifeSite valve was tested for mechanical durability Patients with active infection and those who were posi-
by exposing it to the equivalent of 6000 dialysis treat- tive for hepatitis were excluded. The patients all signed
ments (or 38 years of use) using a standard 14-gauge informed consent, and the appropriate Institutional Re-
dialysis needle. The device was also tested with a pres- view Boards approved the studies. Data on the two stud-
sure of 2000 mm Hg to determine the force required to ies have been combined.
disconnect the cannula from the valve. This was com- Measurements of maximum blood flow were made
pared with a standard chemotherapy port. on each patient using the HT110 Bypass Flow Meter
Tests for hemolysis were conducted using fresh bovine (Transonic Systems, Inc., Ithaca, NY, USA). Recircula-
blood. Forty hours of simulated dialysis was conducted tion was determined by saline dilution using the same
using the LifeSite System consisting of a valve, a cannula, device. The dose of dialysis delivered using the LifeSite
and a 14-gauge dialysis needle. A 15-gauge dialysis nee- System was determined by calculating the patient’s Kt/V.
dle and a 10 French dialysis catheter (Tesio; MedComp, Life table analysis data were calculated using the Kap-
Harleysville, PA, USA) were used as controls. Hemolysis lan–Meier method.
was measured using a test that is very similar to the Bacteremia was determined by blood cultures drawn
Normalized Index of Hemolysis that is widely applied from the arterial bloodline port during dialysis at the
for hemolysis evaluation during in vitro testing of heart- blood flow rate that was being used for the treatment.
assist devices [10]. Tests were performed at two blood Device-related infection was defined as bacteremia in
flow rates: 300 mL/min and 450 mL/min. the absence of any other obvious cause. The incidence
of device-related infection was expressed as infections
Patient studies per 1000 patient days and was calculated using the total
Two pilot clinical studies have been completed, one number of days that the devices were in place and the
in Canada consisting of 13 patients and one in the United total number of device-related infections.
States consisting of 10 patients. Patients and staff were interviewed to determine their
attitude and impressions of the use of the device.The criteria for entry into the study were the need for
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Table 1. Reasons for LifeSitet valve loss
Reason N
Infection
Device related 12
Bacteremia
Non-device related 6
Death 3
Creation of peripheral access 1
Transplant 1
System was 6.8 6 0.97 months (median survival was 5.9
months; range 0.2 to 16.7 months). Although three pa-
tients died during the course of this study, none of these
deaths were related to the study or the LifeSite System.
In two cases, the patients elected to discontinue dialysis
Fig. 5. One-year survival of LifeSitet System. because of severe symptoms from comorbid conditions.
One of these patients had scleroderma; the other had
intractable pain related to multiple collapsed vertebrae.
The incidence of device-related infection was 2.5 infec-RESULTS
tions per 1000 patient-days. Device-related infection oc-
In vitro studies curred in 52.2% of the cases (12 out of 23), resulting in
There was no malfunction or degradation in function valve removal in all cases. These infections occurred at
with repetitive cannulation up to 6000 times using a stan- intervals ranging from 1.8 to 16.7 months. The mean
dard 14-gauge dialysis needle. The cannula disconnect time from implantation to infection was 7.7 6 1.6 months,
force was determined to be 8.4 versus 4.6 pounds for a with a median time of 5.9 months. In two patients, the
standard chemotherapy port (data on file; Vasca, Inc., episode of device-related bacteremia occurred following
Tewksbury, MA, USA). the development of a contact dermatitis related to the
Tests for hemolysis showed that the LifeSite System use of the chlorhexidine solution. In three instances, the
produced less blood damage than either the 15-gauge infection was traced to a break in the protocol estab-
dialysis needle or the 10 French dialysis catheter (P , lished for site preparation and needle cannulation. Seven
0.005 to 0.05) and was deemed to be clinically insignifi- episodes of non-device–related bacteremia were seen in
cant (data on file; Vasca, Inc.). six patients. The LifeSite Systems were removed because
of non-device–related bacteremia in six instances. In four
Patient studies cases, the cannulas were exchanged because of the pres-
The mean age of the patients in this study was 60.78 ence of bacteremia; one of these was device related. The
years, with a range of 20 to 82. Thirteen of the patients valves were not disturbed in this process. The causes of
were male, and 10 were female. Of the 23 patients, 47.8% valve loss are listed in Table 1.
(11 out of 23) had diabetes, and 30.4% (7 out of 23) had The LifeSite System achieved prescription HD blood
hypertension as the cause of the ESRD. flow rates averaging 384.7 6 78.5 mL/min with a venous
The surgical implantation procedures were accom- pressure of 223.2 6 60.3 mm Hg (Fig. 6). No recirculation
plished without difficulty. The time required for implan- was present even at maximum flow rates. Although flow
tation was 60 to 90 minutes. There were no surgical fail- problems did occur occasionally, there were no device
ures; implantation was accomplished in all cases. The removals because of occlusion. The cannulas were treated
LifeSite Systems were used for dialysis immediately fol- with intraluminal instillation of urokinase if a flow greater
lowing surgery. Because of the freshness of the surgical than 300 mL/min could not be achieved for a dialysis
site, some patients did report discomfort at the time of treatment during the course of the study. In one case,
needle cannulation at initial dialysis treatments. Because the cannulas were exchanged because of poor flow. Occa-
of this, oral pain medication was generally given 30 to sionally, blood clots 3 to 4 cm in length were aspirated
45 minutes prior to the start of dialysis. After 10 to 14 when the nurses were withdrawing heparin from the
days, the cannulation process was no longer uncomfort- cannulas at the initiation of dialysis. These clots did not
able, and the use of local or topical anesthesia was not occlude the cannulas and were of no consequence.
required. The mean Kt/V was 1.51. No postdialysis bleeding prob-
The Kaplan–Meier survival data are shown in Figure lems were encountered. No difficulties were experienced
in using the buttonhole technique for needle cannulation.5. The mean duration of device survival of the LifeSite
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in this series were better than has been reported in some
of the studies with tunneled chronic dialysis catheters.
The mean patency rate for tunneled catheters has been
reported to range from 73 to 84 days [11, 12]. The mean
patency rate in this series was 174 days (5.8 months).
Reported device-related infection in association with
tunneled chronic dialysis catheters has ranged from 0.7
to 5.5 per 1000 patient-days [13–18]. The device-related
infection rate of 2.5 infections per 1000 patient-days
noted with the LifeSite System falls about midway within
this reported range. Although this is a preliminary study,
these observations suggest that the LifeSite System has
an improved patency rate and at least a comparable infec-
tion risk profile when compared with tunneled chronic
dialysis catheters.
Unfortunately, infection was not eliminated with the
LifeSite System. Good technique at the time of valve
cannulation and needle removal are important. We have
found that it is possible to exchange the cannulas at-
Fig. 6. Average blood flow. The line (A) represents the line of identity;
tached to the valves without disturbing the valves them-the line (B) is the actual flow rate. Abbreviations are: Qb-actual, blood
flow measured with Transonic HD Monitor; Qb-RPM, blood flow as selves. This is analogous to exchanging a chronic dialysis
indicated on the dialysis machine (r.p.m. meter). catheter in the management of catheter-related bacter-
emia [17–19]. Whether this is appropriate in association
with the LifeSite System has not been validated.
Although flow problems occurred infrequently and noPatient acceptance of the device was favorable, citing
device was lost because of this complication, blood clotsa perception of pain-free cannulations, improved body
3 to 4 cm in length were frequently aspirated from theimage, and improved quality of life. Dialysis facility staff
cannulas at the initiation of a dialysis treatment. Theexpressed a strong acceptance of the device once they had
ability to aspirate these clots was attributed to the largelearned to use it. They cited ease of cannulation and imme-
diameter of the cannula (12 French).diate hemostasis following dialysis as positive points.
The buttonhole technique used for cannulating the
valves offered several advantages. This technique made
DISCUSSION cannulation easier and was performed faster because the
site was constant and easily recognized. After a shortThis study serves to validate the use of the LifeSite
System as an alternative HD access device for chronic period, cannulation of the valve was also painless, a very
welcome feature for these patients who have to undergouse as a HD access system. These devices were easily
placed without complication. They were easily cannu- a needle stick so frequently. Using the same site repeti-
tively also reduces scarring and may eliminate the needlated using a standard 14-gauge dialysis needle and could
be used immediately after placement. The LifeSite Sys- of needle reinsertion because of “bad sticks.” After 156.9
patient-months of using the buttonhole technique, notem had excellent flow characteristics. With flow being
proportional to the diameter of the catheter raised to problems have been encountered.
Acceptance of the LifeSite System among patients andthe fourth power, good flow should be expected with a
12 French cannula. Flows in excess of 400 mL/min were dialysis center staff members has been excellent. Patients
especially favored the pain-free cannulations, improvedroutinely obtained without recirculation. This enabled
the patients in the study to receive very effective dialysis, body image, and resulting improved quality of life. This
latter benefit was attributed at least in part to an abilityobtaining a mean Kt/V of 1.51. This Kt/V was the result
of high flow rates plus the fact that patients were dialyzed to achieve effective dialysis in a population of patients
that had not had adequate dialysis because of accessfor a minimum time of four hours.
In 1995, the mean age of the United States dialysis problems prior to entering the study.
In summary, this clinical study validates the applicabil-population was 60 years, and the incidence of diabetes
was 37.4%. In our study, the mean age was 60.87, and ity of the LifeSite Hemodialysis Access System as a vas-
cular access for chronic HD. The results of this studythe incidence of diabetes was 47.8%. Because of this
increased incidence of diabetes, these patients would be suggest that it has several advantages over tunneled
chronic dialysis catheters. The exact place of this deviceexpected to represent a higher than average risk group.
Nevertheless, the patency and infection rates observed in the armamentarium of the nephrologist dealing with
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panded polytetrafluoroethylene graft fistula for chronic hemodialy-vascular access will depend on further study and experi-
sis. Ann Surg 189:101–105, 1979
ence. However, these data suggest that it can play an 7. Sabanayagam P, Schwartz AB, Soricelli RR, Chinitz J, Lyons
P: Experience with one hundred reinforced expanded PTFE graftsimportant role as a bridge to allow for maturation of a
for angio-access in hemodialysis. Trans Am Soc Artif Intern Organsperipheral access and as an alternative for long-term use 26:582–586, 1980
when a peripheral access is not feasible. The LifeSite 8. Munda R, First MR, Alexander JW, Linnemann CC, Fidler JP,
Kittur D: Polytetrafluoroethylene graft survival in hemodialysis.System may also be ideal as an alternative for patients
JAMA 249:219–222, 1983whose comorbidities would not tolerate the strain of 9. Kherlakian GM, Roedersheimer LR, Arbough JJ, Newmark
KJ, King LR: Comparison of autogenous fistula versus expandedshunt systems as well as patients whose quality-of-life
polytetrafluoroethylene graft fistula for angioaccess in hemodialy-needs demand the discreetness of a subcutaneous system.
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